Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Plasma cell 1Lymphoid 1Genitourinary 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Multiple Myeloma 6Recurrence 4Myelodysplastic Syndromes 4Lymphoma, Non-Hodgkin 4Leukemia, Myeloid, Acute 4Breast Neoplasms 4Prostatic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Pancreatic Neoplasms 2Neoplasm Metastasis 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Hodgkin Disease 2Hematologic Neoplasms 2Glioma 2Diffuse Intrinsic Pontine Glioma 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Blast Crisis 2Thrombocytosis 1Stomach Neoplasms 1Somatostatinoma 1Solid Tumors 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Rhabdoid Tumor 1

Interventions

Cyclophosphamide 10fludarabine phosphate 9Peripheral Blood Stem Cell Transplantation 8Busulfan 8Antilymphocyte Serum 8Mycophenolic Acid 7Whole-Body Irradiation 6Tacrolimus 6Methylprednisolone 6Methotrexate 6Cyclosporine 6Radiotherapy 5Filgrastim 5Cord Blood Stem Cell Transplantation 5Sirolimus 4Rituximab 4Flow Cytometry 4Cytarabine 4Thiotepa 3Melphalan 3Imatinib Mesylate 3Granulocyte Colony-Stimulating Factor 3Etoposide 3Dasatinib 3venetoclax 2ponatinib 2aldesleukin 2Tretinoin 2Therapeutics 2Sunitinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Blast Crisis × Panobinostat × Clear all
NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT00449761 2021-07-15

Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase

Novartis

Phase 2 Terminated
27 enrolled 14 charts
MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡